Hospital Beata Maria Ana

Madrid 73 trials 41 recruiting

73 Registered trials

41 Currently recruiting

Organisation

Hospital Beata Maria Ana

Location

Madrid, Spain

Identifier

ORG-100048975

Address

Calle Del Doctor Esquerdo No. 83, 28007, Spain

Departments

#034003 Oncology
#03403 :Oncología medica
Hematology
IOB Madrid Institute of Oncology
Medical Oncology
Medical Oncology Department
N/A
Oncología
Oncologia Medica
Oncology
Oncology Department
Servicio de Oncologia
Servicio de Oncología Médica
Unidad de Cáncer de Mama
Unidad Oncologica Medica

Clinical trials at this site (73)

Search interface

A phase 2 study to research the safety and efficacy of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with acti… Not authorised

2024-512369-14-00 Non-small cell lung cancer (NSCLC). 4
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-02… Pending

2024-517339-30-00 Advanced Solid Tumors 7
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending

2025-524613-89-00 HER2 positive advanced breast cancer 9
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or V… Recruiting

2025-521966-91-00 Refractory Metastatic Breast Cancer with Liver Dominant 4 2026-03-31
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 HER2-positive breast cancer 4 2026-03-25
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting

2024-520027-88-00 Patients with hormone receptor-positive (HR+) breast ca 4 2026-02-12
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me… Recruiting

2025-521919-39-00 Resected stage IIB, IIC, or III melanoma requiring adju 3 2026-02-10
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity … Recruiting

2025-521562-95-00 Previously Untreated Advanced (Unresectable or Metastat 5 2025-12-30
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting

2024-516869-36-00 Relapsed or refractory B-cell malignancies: chronic lym 1 2025-02-17
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRA… Recruiting

2024-512515-45-01 Non-Small Cell Lung Cancer 1 2026-04-10
A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting

2025-522012-16-00 Breast Cancer 4 2026-03-13
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer Recruiting

2024-514661-19-01 Advanced ER+/HER2- Breast Cancer 1 2026-02-18
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting

2025-521003-52-00 HER2 Expressing Advanced Breast Cancer 9 2025-12-19
To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan… Recruiting

2025-521128-31-00 Locally Advanced or Metastatic Estrogen Receptor-Positi 9 2025-12-18